A Phase I/II, Open-Label, Dose Escalation Followed by Single-Arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

被引：0
|
作者：
Ronen, O. [1 ]
Shickler, M. [2 ]
Reuveni, H. [2 ]
Israel, I. [2 ]
Haviv, I. [2 ]
Waymack, P. J. [2 ]
Cohen, E. [3 ]
机构：
[1] Galilee Med Ctr, Nahariyya, Israel
[2] Kitov Pharma, Tel Aviv, Israel
[3] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 106卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页码：1182 / 1183
页数：2
相关论文
共 50 条
  • [41] Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
    Sacco, Assuntina G.
    Chen, Ruifeng
    Worden, Francis P.
    Wong, Deborah J. L.
    Adkins, Douglas
    Swiecicki, Paul
    Chai-Ho, Wanxing
    Oppelt, Peter
    Ghosh, Debanjali
    Bykowski, Julie
    Molinolo, Alfredo
    Pittman, Emily
    Estrada, M. Valeria
    Gold, Kathryn
    Daniels, Gregory
    Lippman, Scott M.
    Natsuhara, Amanda
    Messer, Karen
    Cohen, Ezra E. W.
    LANCET ONCOLOGY, 2021, 22 (06): : 883 - 892
  • [42] A phase I study of everolimus in combination with cetuximab and cisplatin as first-line therapy inrecurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Chung, Christine H.
    Wang, Hao
    Tsottles, Nancy
    Gourin, Christine Gail
    Agrawal, Nishant
    Molinolo, Alfredo
    Gutkind, Silvio
    Forastiere, Arlene A.
    Marur, Shanthi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma
    Kilgour, James M.
    Shah, Aatman
    Urman, Nicole M.
    Eichstadt, Shaundra
    Do, Hanh N.
    Bailey, Irene
    Mirza, Amar
    Li, Shufeng
    Oro, Anthony E.
    Aasi, Sumaira Z.
    Sarin, Kavita Y.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4717 - 4725
  • [44] Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
    Siu, Lillian L.
    Papadopoulos, Kyriakos P.
    Tsai, Frank Yung-Chin
    Hansen, Aaron Richard
    Robbins, Paul B.
    Li, Xia
    Lai, Dominic W.
    Blake-Haskins, John A.
    Fury, Matthew G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Kim, S-B.
    Keam, B.
    Shin, S.
    Chae, Y. S.
    Seo, S.
    Park, K.
    Kim, T. M.
    Park, L. C.
    Hong, S-B.
    Lim, E.
    Lee, S.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S667 - S668
  • [46] A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ABEMACICLIB IN PATIENTS WITH RECURRENT OLIGODENDROGLIOMA: TRIALS IN PROGRESS
    Bagley, Stephen
    Nasrallah, MacLean
    O'Rourke, Donald
    Hussain, Jasmin
    Maloney-Wilensky, Eileen
    Prior, Timothy
    Brem, Steven
    Desai, Arati
    NEURO-ONCOLOGY, 2019, 21 : 219 - 219
  • [47] Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    A. Ruzsa
    M. Sen
    M. Evans
    L. W. Lee
    K. Hideghety
    S. Rottey
    P. Klimak
    P. Holeckova
    J. Fayette
    T. Csoszi
    J. Erfan
    U. Forssmann
    T. Goddemeier
    A. Bexon
    C. Nutting
    Investigational New Drugs, 2014, 32 : 1278 - 1284
  • [48] Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-na⟨ve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Ruzsa, A.
    Sen, M.
    Evans, M.
    Lee, L. W.
    Hideghety, K.
    Rottey, S.
    Klimak, P.
    Holeckova, P.
    Fayette, J.
    Csoszi, T.
    Erfan, J.
    Forssmann, U.
    Goddemeier, T.
    Bexon, A.
    Nutting, C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1278 - 1284
  • [49] Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Duwuri, Umamaheswar
    Ferris, Robert L.
    Ohr, James
    Gooding, William E.
    Kim, Seungwon
    Johnson, Jonas Talmadge
    Grandis, Jennifer R.
    Stabile, Laura P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Dunn, L. A.
    Fury, M. G.
    Xiao, H.
    Baxi, S. S.
    Sherman, E. J.
    Korte, S.
    Pfister, C.
    Haque, S.
    Katabi, N.
    Ho, A. L.
    Pfister, D. G.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2533 - 2538
12345